Global Oral Vaccine for Human Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
The global Oral Vaccine for Human market size is projected to grow from US$ 2484.8 million in 2022 to US$ 3707.1 million in 2029; it is expected to grow at a CAGR of 5.9% from 2023 to 2029.
United States market for Oral Vaccine for Human is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Oral Vaccine for Human is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Oral Vaccine for Human is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Oral Vaccine for Human players cover Merck, GSK, Sanofi, Lanzhou Institute, Serum Institute, Valneva, Shanghai United Cell, Bibcol and PaxVax, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Orally administered vaccines are of interest, as they elicit both systemic and mucosal immunities, in which mucosal immunity would neutralize the mucosa invading pathogen before the onset of an infection.
LPI (LP Information)' newest research report, the “Oral Vaccine for Human Industry Forecast” looks at past sales and reviews total world Oral Vaccine for Human sales in 2022, providing a comprehensive analysis by region and market sector of projected Oral Vaccine for Human sales for 2023 through 2029. With Oral Vaccine for Human sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oral Vaccine for Human industry.
This Insight Report provides a comprehensive analysis of the global Oral Vaccine for Human landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Oral Vaccine for Human portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Oral Vaccine for Human market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oral Vaccine for Human and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oral Vaccine for Human.
This report presents a comprehensive overview, market shares, and growth opportunities of Oral Vaccine for Human market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Oral Vaccine for Human market?
What factors are driving Oral Vaccine for Human market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Oral Vaccine for Human market opportunities vary by end market size?
How does Oral Vaccine for Human break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
The global Oral Vaccine for Human market size is projected to grow from US$ 2484.8 million in 2022 to US$ 3707.1 million in 2029; it is expected to grow at a CAGR of 5.9% from 2023 to 2029.
United States market for Oral Vaccine for Human is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Oral Vaccine for Human is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Oral Vaccine for Human is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Oral Vaccine for Human players cover Merck, GSK, Sanofi, Lanzhou Institute, Serum Institute, Valneva, Shanghai United Cell, Bibcol and PaxVax, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Orally administered vaccines are of interest, as they elicit both systemic and mucosal immunities, in which mucosal immunity would neutralize the mucosa invading pathogen before the onset of an infection.
LPI (LP Information)' newest research report, the “Oral Vaccine for Human Industry Forecast” looks at past sales and reviews total world Oral Vaccine for Human sales in 2022, providing a comprehensive analysis by region and market sector of projected Oral Vaccine for Human sales for 2023 through 2029. With Oral Vaccine for Human sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oral Vaccine for Human industry.
This Insight Report provides a comprehensive analysis of the global Oral Vaccine for Human landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Oral Vaccine for Human portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Oral Vaccine for Human market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oral Vaccine for Human and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oral Vaccine for Human.
This report presents a comprehensive overview, market shares, and growth opportunities of Oral Vaccine for Human market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Rotavirus Vaccine
- Cholera Vaccine
- Oral Polio Vaccine
- Other
- Public
- Private
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Merck
- GSK
- Sanofi
- Lanzhou Institute
- Serum Institute
- Valneva
- Shanghai United Cell
- Bibcol
- PaxVax
- Vabiotech
- Tiantan Biological
- EuBiologics
- Panacea Biotec Ltd
- Bio-Med
- Halfkin Bio-Pharmaceuticals
What is the 10-year outlook for the global Oral Vaccine for Human market?
What factors are driving Oral Vaccine for Human market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Oral Vaccine for Human market opportunities vary by end market size?
How does Oral Vaccine for Human break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Oral Vaccine for Human Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Oral Vaccine for Human by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Oral Vaccine for Human by Country/Region, 2018, 2022 & 2029
2.2 Oral Vaccine for Human Segment by Type
2.2.1 Rotavirus Vaccine
2.2.2 Cholera Vaccine
2.2.3 Oral Polio Vaccine
2.2.4 Other
2.3 Oral Vaccine for Human Sales by Type
2.3.1 Global Oral Vaccine for Human Sales Market Share by Type (2018-2023)
2.3.2 Global Oral Vaccine for Human Revenue and Market Share by Type (2018-2023)
2.3.3 Global Oral Vaccine for Human Sale Price by Type (2018-2023)
2.4 Oral Vaccine for Human Segment by Application
2.4.1 Public
2.4.2 Private
2.5 Oral Vaccine for Human Sales by Application
2.5.1 Global Oral Vaccine for Human Sale Market Share by Application (2018-2023)
2.5.2 Global Oral Vaccine for Human Revenue and Market Share by Application (2018-2023)
2.5.3 Global Oral Vaccine for Human Sale Price by Application (2018-2023)
3 GLOBAL ORAL VACCINE FOR HUMAN BY COMPANY
3.1 Global Oral Vaccine for Human Breakdown Data by Company
3.1.1 Global Oral Vaccine for Human Annual Sales by Company (2018-2023)
3.1.2 Global Oral Vaccine for Human Sales Market Share by Company (2018-2023)
3.2 Global Oral Vaccine for Human Annual Revenue by Company (2018-2023)
3.2.1 Global Oral Vaccine for Human Revenue by Company (2018-2023)
3.2.2 Global Oral Vaccine for Human Revenue Market Share by Company (2018-2023)
3.3 Global Oral Vaccine for Human Sale Price by Company
3.4 Key Manufacturers Oral Vaccine for Human Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Oral Vaccine for Human Product Location Distribution
3.4.2 Players Oral Vaccine for Human Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR ORAL VACCINE FOR HUMAN BY GEOGRAPHIC REGION
4.1 World Historic Oral Vaccine for Human Market Size by Geographic Region (2018-2023)
4.1.1 Global Oral Vaccine for Human Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Oral Vaccine for Human Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Oral Vaccine for Human Market Size by Country/Region (2018-2023)
4.2.1 Global Oral Vaccine for Human Annual Sales by Country/Region (2018-2023)
4.2.2 Global Oral Vaccine for Human Annual Revenue by Country/Region (2018-2023)
4.3 Americas Oral Vaccine for Human Sales Growth
4.4 APAC Oral Vaccine for Human Sales Growth
4.5 Europe Oral Vaccine for Human Sales Growth
4.6 Middle East & Africa Oral Vaccine for Human Sales Growth
5 AMERICAS
5.1 Americas Oral Vaccine for Human Sales by Country
5.1.1 Americas Oral Vaccine for Human Sales by Country (2018-2023)
5.1.2 Americas Oral Vaccine for Human Revenue by Country (2018-2023)
5.2 Americas Oral Vaccine for Human Sales by Type
5.3 Americas Oral Vaccine for Human Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oral Vaccine for Human Sales by Region
6.1.1 APAC Oral Vaccine for Human Sales by Region (2018-2023)
6.1.2 APAC Oral Vaccine for Human Revenue by Region (2018-2023)
6.2 APAC Oral Vaccine for Human Sales by Type
6.3 APAC Oral Vaccine for Human Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Oral Vaccine for Human by Country
7.1.1 Europe Oral Vaccine for Human Sales by Country (2018-2023)
7.1.2 Europe Oral Vaccine for Human Revenue by Country (2018-2023)
7.2 Europe Oral Vaccine for Human Sales by Type
7.3 Europe Oral Vaccine for Human Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Oral Vaccine for Human by Country
8.1.1 Middle East & Africa Oral Vaccine for Human Sales by Country (2018-2023)
8.1.2 Middle East & Africa Oral Vaccine for Human Revenue by Country (2018-2023)
8.2 Middle East & Africa Oral Vaccine for Human Sales by Type
8.3 Middle East & Africa Oral Vaccine for Human Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Oral Vaccine for Human
10.3 Manufacturing Process Analysis of Oral Vaccine for Human
10.4 Industry Chain Structure of Oral Vaccine for Human
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Oral Vaccine for Human Distributors
11.3 Oral Vaccine for Human Customer
12 WORLD FORECAST REVIEW FOR ORAL VACCINE FOR HUMAN BY GEOGRAPHIC REGION
12.1 Global Oral Vaccine for Human Market Size Forecast by Region
12.1.1 Global Oral Vaccine for Human Forecast by Region (2024-2029)
12.1.2 Global Oral Vaccine for Human Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Oral Vaccine for Human Forecast by Type
12.7 Global Oral Vaccine for Human Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Merck
13.1.1 Merck Company Information
13.1.2 Merck Oral Vaccine for Human Product Portfolios and Specifications
13.1.3 Merck Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Merck Main Business Overview
13.1.5 Merck Latest Developments
13.2 GSK
13.2.1 GSK Company Information
13.2.2 GSK Oral Vaccine for Human Product Portfolios and Specifications
13.2.3 GSK Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 GSK Main Business Overview
13.2.5 GSK Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi Oral Vaccine for Human Product Portfolios and Specifications
13.3.3 Sanofi Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 Lanzhou Institute
13.4.1 Lanzhou Institute Company Information
13.4.2 Lanzhou Institute Oral Vaccine for Human Product Portfolios and Specifications
13.4.3 Lanzhou Institute Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Lanzhou Institute Main Business Overview
13.4.5 Lanzhou Institute Latest Developments
13.5 Serum Institute
13.5.1 Serum Institute Company Information
13.5.2 Serum Institute Oral Vaccine for Human Product Portfolios and Specifications
13.5.3 Serum Institute Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Serum Institute Main Business Overview
13.5.5 Serum Institute Latest Developments
13.6 Valneva
13.6.1 Valneva Company Information
13.6.2 Valneva Oral Vaccine for Human Product Portfolios and Specifications
13.6.3 Valneva Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Valneva Main Business Overview
13.6.5 Valneva Latest Developments
13.7 Shanghai United Cell
13.7.1 Shanghai United Cell Company Information
13.7.2 Shanghai United Cell Oral Vaccine for Human Product Portfolios and Specifications
13.7.3 Shanghai United Cell Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Shanghai United Cell Main Business Overview
13.7.5 Shanghai United Cell Latest Developments
13.8 Bibcol
13.8.1 Bibcol Company Information
13.8.2 Bibcol Oral Vaccine for Human Product Portfolios and Specifications
13.8.3 Bibcol Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Bibcol Main Business Overview
13.8.5 Bibcol Latest Developments
13.9 PaxVax
13.9.1 PaxVax Company Information
13.9.2 PaxVax Oral Vaccine for Human Product Portfolios and Specifications
13.9.3 PaxVax Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 PaxVax Main Business Overview
13.9.5 PaxVax Latest Developments
13.10 Vabiotech
13.10.1 Vabiotech Company Information
13.10.2 Vabiotech Oral Vaccine for Human Product Portfolios and Specifications
13.10.3 Vabiotech Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Vabiotech Main Business Overview
13.10.5 Vabiotech Latest Developments
13.11 Tiantan Biological
13.11.1 Tiantan Biological Company Information
13.11.2 Tiantan Biological Oral Vaccine for Human Product Portfolios and Specifications
13.11.3 Tiantan Biological Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Tiantan Biological Main Business Overview
13.11.5 Tiantan Biological Latest Developments
13.12 EuBiologics
13.12.1 EuBiologics Company Information
13.12.2 EuBiologics Oral Vaccine for Human Product Portfolios and Specifications
13.12.3 EuBiologics Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 EuBiologics Main Business Overview
13.12.5 EuBiologics Latest Developments
13.13 Panacea Biotec Ltd
13.13.1 Panacea Biotec Ltd Company Information
13.13.2 Panacea Biotec Ltd Oral Vaccine for Human Product Portfolios and Specifications
13.13.3 Panacea Biotec Ltd Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Panacea Biotec Ltd Main Business Overview
13.13.5 Panacea Biotec Ltd Latest Developments
13.14 Bio-Med
13.14.1 Bio-Med Company Information
13.14.2 Bio-Med Oral Vaccine for Human Product Portfolios and Specifications
13.14.3 Bio-Med Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Bio-Med Main Business Overview
13.14.5 Bio-Med Latest Developments
13.15 Halfkin Bio-Pharmaceuticals
13.15.1 Halfkin Bio-Pharmaceuticals Company Information
13.15.2 Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Product Portfolios and Specifications
13.15.3 Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Halfkin Bio-Pharmaceuticals Main Business Overview
13.15.5 Halfkin Bio-Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Oral Vaccine for Human Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Oral Vaccine for Human by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Oral Vaccine for Human by Country/Region, 2018, 2022 & 2029
2.2 Oral Vaccine for Human Segment by Type
2.2.1 Rotavirus Vaccine
2.2.2 Cholera Vaccine
2.2.3 Oral Polio Vaccine
2.2.4 Other
2.3 Oral Vaccine for Human Sales by Type
2.3.1 Global Oral Vaccine for Human Sales Market Share by Type (2018-2023)
2.3.2 Global Oral Vaccine for Human Revenue and Market Share by Type (2018-2023)
2.3.3 Global Oral Vaccine for Human Sale Price by Type (2018-2023)
2.4 Oral Vaccine for Human Segment by Application
2.4.1 Public
2.4.2 Private
2.5 Oral Vaccine for Human Sales by Application
2.5.1 Global Oral Vaccine for Human Sale Market Share by Application (2018-2023)
2.5.2 Global Oral Vaccine for Human Revenue and Market Share by Application (2018-2023)
2.5.3 Global Oral Vaccine for Human Sale Price by Application (2018-2023)
3 GLOBAL ORAL VACCINE FOR HUMAN BY COMPANY
3.1 Global Oral Vaccine for Human Breakdown Data by Company
3.1.1 Global Oral Vaccine for Human Annual Sales by Company (2018-2023)
3.1.2 Global Oral Vaccine for Human Sales Market Share by Company (2018-2023)
3.2 Global Oral Vaccine for Human Annual Revenue by Company (2018-2023)
3.2.1 Global Oral Vaccine for Human Revenue by Company (2018-2023)
3.2.2 Global Oral Vaccine for Human Revenue Market Share by Company (2018-2023)
3.3 Global Oral Vaccine for Human Sale Price by Company
3.4 Key Manufacturers Oral Vaccine for Human Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Oral Vaccine for Human Product Location Distribution
3.4.2 Players Oral Vaccine for Human Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR ORAL VACCINE FOR HUMAN BY GEOGRAPHIC REGION
4.1 World Historic Oral Vaccine for Human Market Size by Geographic Region (2018-2023)
4.1.1 Global Oral Vaccine for Human Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Oral Vaccine for Human Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Oral Vaccine for Human Market Size by Country/Region (2018-2023)
4.2.1 Global Oral Vaccine for Human Annual Sales by Country/Region (2018-2023)
4.2.2 Global Oral Vaccine for Human Annual Revenue by Country/Region (2018-2023)
4.3 Americas Oral Vaccine for Human Sales Growth
4.4 APAC Oral Vaccine for Human Sales Growth
4.5 Europe Oral Vaccine for Human Sales Growth
4.6 Middle East & Africa Oral Vaccine for Human Sales Growth
5 AMERICAS
5.1 Americas Oral Vaccine for Human Sales by Country
5.1.1 Americas Oral Vaccine for Human Sales by Country (2018-2023)
5.1.2 Americas Oral Vaccine for Human Revenue by Country (2018-2023)
5.2 Americas Oral Vaccine for Human Sales by Type
5.3 Americas Oral Vaccine for Human Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oral Vaccine for Human Sales by Region
6.1.1 APAC Oral Vaccine for Human Sales by Region (2018-2023)
6.1.2 APAC Oral Vaccine for Human Revenue by Region (2018-2023)
6.2 APAC Oral Vaccine for Human Sales by Type
6.3 APAC Oral Vaccine for Human Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Oral Vaccine for Human by Country
7.1.1 Europe Oral Vaccine for Human Sales by Country (2018-2023)
7.1.2 Europe Oral Vaccine for Human Revenue by Country (2018-2023)
7.2 Europe Oral Vaccine for Human Sales by Type
7.3 Europe Oral Vaccine for Human Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Oral Vaccine for Human by Country
8.1.1 Middle East & Africa Oral Vaccine for Human Sales by Country (2018-2023)
8.1.2 Middle East & Africa Oral Vaccine for Human Revenue by Country (2018-2023)
8.2 Middle East & Africa Oral Vaccine for Human Sales by Type
8.3 Middle East & Africa Oral Vaccine for Human Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Oral Vaccine for Human
10.3 Manufacturing Process Analysis of Oral Vaccine for Human
10.4 Industry Chain Structure of Oral Vaccine for Human
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Oral Vaccine for Human Distributors
11.3 Oral Vaccine for Human Customer
12 WORLD FORECAST REVIEW FOR ORAL VACCINE FOR HUMAN BY GEOGRAPHIC REGION
12.1 Global Oral Vaccine for Human Market Size Forecast by Region
12.1.1 Global Oral Vaccine for Human Forecast by Region (2024-2029)
12.1.2 Global Oral Vaccine for Human Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Oral Vaccine for Human Forecast by Type
12.7 Global Oral Vaccine for Human Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Merck
13.1.1 Merck Company Information
13.1.2 Merck Oral Vaccine for Human Product Portfolios and Specifications
13.1.3 Merck Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Merck Main Business Overview
13.1.5 Merck Latest Developments
13.2 GSK
13.2.1 GSK Company Information
13.2.2 GSK Oral Vaccine for Human Product Portfolios and Specifications
13.2.3 GSK Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 GSK Main Business Overview
13.2.5 GSK Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi Oral Vaccine for Human Product Portfolios and Specifications
13.3.3 Sanofi Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 Lanzhou Institute
13.4.1 Lanzhou Institute Company Information
13.4.2 Lanzhou Institute Oral Vaccine for Human Product Portfolios and Specifications
13.4.3 Lanzhou Institute Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Lanzhou Institute Main Business Overview
13.4.5 Lanzhou Institute Latest Developments
13.5 Serum Institute
13.5.1 Serum Institute Company Information
13.5.2 Serum Institute Oral Vaccine for Human Product Portfolios and Specifications
13.5.3 Serum Institute Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Serum Institute Main Business Overview
13.5.5 Serum Institute Latest Developments
13.6 Valneva
13.6.1 Valneva Company Information
13.6.2 Valneva Oral Vaccine for Human Product Portfolios and Specifications
13.6.3 Valneva Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Valneva Main Business Overview
13.6.5 Valneva Latest Developments
13.7 Shanghai United Cell
13.7.1 Shanghai United Cell Company Information
13.7.2 Shanghai United Cell Oral Vaccine for Human Product Portfolios and Specifications
13.7.3 Shanghai United Cell Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Shanghai United Cell Main Business Overview
13.7.5 Shanghai United Cell Latest Developments
13.8 Bibcol
13.8.1 Bibcol Company Information
13.8.2 Bibcol Oral Vaccine for Human Product Portfolios and Specifications
13.8.3 Bibcol Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Bibcol Main Business Overview
13.8.5 Bibcol Latest Developments
13.9 PaxVax
13.9.1 PaxVax Company Information
13.9.2 PaxVax Oral Vaccine for Human Product Portfolios and Specifications
13.9.3 PaxVax Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 PaxVax Main Business Overview
13.9.5 PaxVax Latest Developments
13.10 Vabiotech
13.10.1 Vabiotech Company Information
13.10.2 Vabiotech Oral Vaccine for Human Product Portfolios and Specifications
13.10.3 Vabiotech Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Vabiotech Main Business Overview
13.10.5 Vabiotech Latest Developments
13.11 Tiantan Biological
13.11.1 Tiantan Biological Company Information
13.11.2 Tiantan Biological Oral Vaccine for Human Product Portfolios and Specifications
13.11.3 Tiantan Biological Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Tiantan Biological Main Business Overview
13.11.5 Tiantan Biological Latest Developments
13.12 EuBiologics
13.12.1 EuBiologics Company Information
13.12.2 EuBiologics Oral Vaccine for Human Product Portfolios and Specifications
13.12.3 EuBiologics Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 EuBiologics Main Business Overview
13.12.5 EuBiologics Latest Developments
13.13 Panacea Biotec Ltd
13.13.1 Panacea Biotec Ltd Company Information
13.13.2 Panacea Biotec Ltd Oral Vaccine for Human Product Portfolios and Specifications
13.13.3 Panacea Biotec Ltd Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Panacea Biotec Ltd Main Business Overview
13.13.5 Panacea Biotec Ltd Latest Developments
13.14 Bio-Med
13.14.1 Bio-Med Company Information
13.14.2 Bio-Med Oral Vaccine for Human Product Portfolios and Specifications
13.14.3 Bio-Med Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Bio-Med Main Business Overview
13.14.5 Bio-Med Latest Developments
13.15 Halfkin Bio-Pharmaceuticals
13.15.1 Halfkin Bio-Pharmaceuticals Company Information
13.15.2 Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Product Portfolios and Specifications
13.15.3 Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Halfkin Bio-Pharmaceuticals Main Business Overview
13.15.5 Halfkin Bio-Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Oral Vaccine for Human Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Oral Vaccine for Human Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Rotavirus Vaccine
Table 4. Major Players of Cholera Vaccine
Table 5. Major Players of Oral Polio Vaccine
Table 6. Major Players of Other
Table 7. Global Oral Vaccine for Human Sales by Type (2018-2023) & (K Units)
Table 8. Global Oral Vaccine for Human Sales Market Share by Type (2018-2023)
Table 9. Global Oral Vaccine for Human Revenue by Type (2018-2023) & ($ million)
Table 10. Global Oral Vaccine for Human Revenue Market Share by Type (2018-2023)
Table 11. Global Oral Vaccine for Human Sale Price by Type (2018-2023) & (US$/Unit)
Table 12. Global Oral Vaccine for Human Sales by Application (2018-2023) & (K Units)
Table 13. Global Oral Vaccine for Human Sales Market Share by Application (2018-2023)
Table 14. Global Oral Vaccine for Human Revenue by Application (2018-2023)
Table 15. Global Oral Vaccine for Human Revenue Market Share by Application (2018-2023)
Table 16. Global Oral Vaccine for Human Sale Price by Application (2018-2023) & (US$/Unit)
Table 17. Global Oral Vaccine for Human Sales by Company (2018-2023) & (K Units)
Table 18. Global Oral Vaccine for Human Sales Market Share by Company (2018-2023)
Table 19. Global Oral Vaccine for Human Revenue by Company (2018-2023) ($ Millions)
Table 20. Global Oral Vaccine for Human Revenue Market Share by Company (2018-2023)
Table 21. Global Oral Vaccine for Human Sale Price by Company (2018-2023) & (US$/Unit)
Table 22. Key Manufacturers Oral Vaccine for Human Producing Area Distribution and Sales Area
Table 23. Players Oral Vaccine for Human Products Offered
Table 24. Oral Vaccine for Human Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Oral Vaccine for Human Sales by Geographic Region (2018-2023) & (K Units)
Table 28. Global Oral Vaccine for Human Sales Market Share Geographic Region (2018-2023)
Table 29. Global Oral Vaccine for Human Revenue by Geographic Region (2018-2023) & ($ millions)
Table 30. Global Oral Vaccine for Human Revenue Market Share by Geographic Region (2018-2023)
Table 31. Global Oral Vaccine for Human Sales by Country/Region (2018-2023) & (K Units)
Table 32. Global Oral Vaccine for Human Sales Market Share by Country/Region (2018-2023)
Table 33. Global Oral Vaccine for Human Revenue by Country/Region (2018-2023) & ($ millions)
Table 34. Global Oral Vaccine for Human Revenue Market Share by Country/Region (2018-2023)
Table 35. Americas Oral Vaccine for Human Sales by Country (2018-2023) & (K Units)
Table 36. Americas Oral Vaccine for Human Sales Market Share by Country (2018-2023)
Table 37. Americas Oral Vaccine for Human Revenue by Country (2018-2023) & ($ Millions)
Table 38. Americas Oral Vaccine for Human Revenue Market Share by Country (2018-2023)
Table 39. Americas Oral Vaccine for Human Sales by Type (2018-2023) & (K Units)
Table 40. Americas Oral Vaccine for Human Sales by Application (2018-2023) & (K Units)
Table 41. APAC Oral Vaccine for Human Sales by Region (2018-2023) & (K Units)
Table 42. APAC Oral Vaccine for Human Sales Market Share by Region (2018-2023)
Table 43. APAC Oral Vaccine for Human Revenue by Region (2018-2023) & ($ Millions)
Table 44. APAC Oral Vaccine for Human Revenue Market Share by Region (2018-2023)
Table 45. APAC Oral Vaccine for Human Sales by Type (2018-2023) & (K Units)
Table 46. APAC Oral Vaccine for Human Sales by Application (2018-2023) & (K Units)
Table 47. Europe Oral Vaccine for Human Sales by Country (2018-2023) & (K Units)
Table 48. Europe Oral Vaccine for Human Sales Market Share by Country (2018-2023)
Table 49. Europe Oral Vaccine for Human Revenue by Country (2018-2023) & ($ Millions)
Table 50. Europe Oral Vaccine for Human Revenue Market Share by Country (2018-2023)
Table 51. Europe Oral Vaccine for Human Sales by Type (2018-2023) & (K Units)
Table 52. Europe Oral Vaccine for Human Sales by Application (2018-2023) & (K Units)
Table 53. Middle East & Africa Oral Vaccine for Human Sales by Country (2018-2023) & (K Units)
Table 54. Middle East & Africa Oral Vaccine for Human Sales Market Share by Country (2018-2023)
Table 55. Middle East & Africa Oral Vaccine for Human Revenue by Country (2018-2023) & ($ Millions)
Table 56. Middle East & Africa Oral Vaccine for Human Revenue Market Share by Country (2018-2023)
Table 57. Middle East & Africa Oral Vaccine for Human Sales by Type (2018-2023) & (K Units)
Table 58. Middle East & Africa Oral Vaccine for Human Sales by Application (2018-2023) & (K Units)
Table 59. Key Market Drivers & Growth Opportunities of Oral Vaccine for Human
Table 60. Key Market Challenges & Risks of Oral Vaccine for Human
Table 61. Key Industry Trends of Oral Vaccine for Human
Table 62. Oral Vaccine for Human Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Oral Vaccine for Human Distributors List
Table 65. Oral Vaccine for Human Customer List
Table 66. Global Oral Vaccine for Human Sales Forecast by Region (2024-2029) & (K Units)
Table 67. Global Oral Vaccine for Human Revenue Forecast by Region (2024-2029) & ($ millions)
Table 68. Americas Oral Vaccine for Human Sales Forecast by Country (2024-2029) & (K Units)
Table 69. Americas Oral Vaccine for Human Revenue Forecast by Country (2024-2029) & ($ millions)
Table 70. APAC Oral Vaccine for Human Sales Forecast by Region (2024-2029) & (K Units)
Table 71. APAC Oral Vaccine for Human Revenue Forecast by Region (2024-2029) & ($ millions)
Table 72. Europe Oral Vaccine for Human Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Europe Oral Vaccine for Human Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Middle East & Africa Oral Vaccine for Human Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Middle East & Africa Oral Vaccine for Human Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Global Oral Vaccine for Human Sales Forecast by Type (2024-2029) & (K Units)
Table 77. Global Oral Vaccine for Human Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 78. Global Oral Vaccine for Human Sales Forecast by Application (2024-2029) & (K Units)
Table 79. Global Oral Vaccine for Human Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 80. Merck Basic Information, Oral Vaccine for Human Manufacturing Base, Sales Area and Its Competitors
Table 81. Merck Oral Vaccine for Human Product Portfolios and Specifications
Table 82. Merck Oral Vaccine for Human Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Merck Main Business
Table 84. Merck Latest Developments
Table 85. GSK Basic Information, Oral Vaccine for Human Manufacturing Base, Sales Area and Its Competitors
Table 86. GSK Oral Vaccine for Human Product Portfolios and Specifications
Table 87. GSK Oral Vaccine for Human Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. GSK Main Business
Table 89. GSK Latest Developments
Table 90. Sanofi Basic Information, Oral Vaccine for Human Manufacturing Base, Sales Area and Its Competitors
Table 91. Sanofi Oral Vaccine for Human Product Portfolios and Specifications
Table 92. Sanofi Oral Vaccine for Human Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Sanofi Main Business
Table 94. Sanofi Latest Developments
Table 95. Lanzhou Institute Basic Information, Oral Vaccine for Human Manufacturing Base, Sales Area and Its Competitors
Table 96. Lanzhou Institute Oral Vaccine for Human Product Portfolios and Specifications
Table 97. Lanzhou Institute Oral Vaccine for Human Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Lanzhou Institute Main Business
Table 99. Lanzhou Institute Latest Developments
Table 100. Serum Institute Basic Information, Oral Vaccine for Human Manufacturing Base, Sales Area and Its Competitors
Table 101. Serum Institute Oral Vaccine for Human Product Portfolios and Specifications
Table 102. Serum Institute Oral Vaccine for Human Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Serum Institute Main Business
Table 104. Serum Institute Latest Developments
Table 105. Valneva Basic Information, Oral Vaccine for Human Manufacturing Base, Sales Area and Its Competitors
Table 106. Valneva Oral Vaccine for Human Product Portfolios and Specifications
Table 107. Valneva Oral Vaccine for Human Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Valneva Main Business
Table 109. Valneva Latest Developments
Table 110. Shanghai United Cell Basic Information, Oral Vaccine for Human Manufacturing Base, Sales Area and Its Competitors
Table 111. Shanghai United Cell Oral Vaccine for Human Product Portfolios and Specifications
Table 112. Shanghai United Cell Oral Vaccine for Human Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Shanghai United Cell Main Business
Table 114. Shanghai United Cell Latest Developments
Table 115. Bibcol Basic Information, Oral Vaccine for Human Manufacturing Base, Sales Area and Its Competitors
Table 116. Bibcol Oral Vaccine for Human Product Portfolios and Specifications
Table 117. Bibcol Oral Vaccine for Human Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. Bibcol Main Business
Table 119. Bibcol Latest Developments
Table 120. PaxVax Basic Information, Oral Vaccine for Human Manufacturing Base, Sales Area and Its Competitors
Table 121. PaxVax Oral Vaccine for Human Product Portfolios and Specifications
Table 122. PaxVax Oral Vaccine for Human Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. PaxVax Main Business
Table 124. PaxVax Latest Developments
Table 125. Vabiotech Basic Information, Oral Vaccine for Human Manufacturing Base, Sales Area and Its Competitors
Table 126. Vabiotech Oral Vaccine for Human Product Portfolios and Specifications
Table 127. Vabiotech Oral Vaccine for Human Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 128. Vabiotech Main Business
Table 129. Vabiotech Latest Developments
Table 130. Tiantan Biological Basic Information, Oral Vaccine for Human Manufacturing Base, Sales Area and Its Competitors
Table 131. Tiantan Biological Oral Vaccine for Human Product Portfolios and Specifications
Table 132. Tiantan Biological Oral Vaccine for Human Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 133. Tiantan Biological Main Business
Table 134. Tiantan Biological Latest Developments
Table 135. EuBiologics Basic Information, Oral Vaccine for Human Manufacturing Base, Sales Area and Its Competitors
Table 136. EuBiologics Oral Vaccine for Human Product Portfolios and Specifications
Table 137. EuBiologics Oral Vaccine for Human Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 138. EuBiologics Main Business
Table 139. EuBiologics Latest Developments
Table 140. Panacea Biotec Ltd Basic Information, Oral Vaccine for Human Manufacturing Base, Sales Area and Its Competitors
Table 141. Panacea Biotec Ltd Oral Vaccine for Human Product Portfolios and Specifications
Table 142. Panacea Biotec Ltd Oral Vaccine for Human Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 143. Panacea Biotec Ltd Main Business
Table 144. Panacea Biotec Ltd Latest Developments
Table 145. Bio-Med Basic Information, Oral Vaccine for Human Manufacturing Base, Sales Area and Its Competitors
Table 146. Bio-Med Oral Vaccine for Human Product Portfolios and Specifications
Table 147. Bio-Med Oral Vaccine for Human Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 148. Bio-Med Main Business
Table 149. Bio-Med Latest Developments
Table 150. Halfkin Bio-Pharmaceuticals Basic Information, Oral Vaccine for Human Manufacturing Base, Sales Area and Its Competitors
Table 151. Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Product Portfolios and Specifications
Table 152. Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 153. Halfkin Bio-Pharmaceuticals Main Business
Table 154. Halfkin Bio-Pharmaceuticals Latest Developments
Table 1. Oral Vaccine for Human Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Oral Vaccine for Human Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Rotavirus Vaccine
Table 4. Major Players of Cholera Vaccine
Table 5. Major Players of Oral Polio Vaccine
Table 6. Major Players of Other
Table 7. Global Oral Vaccine for Human Sales by Type (2018-2023) & (K Units)
Table 8. Global Oral Vaccine for Human Sales Market Share by Type (2018-2023)
Table 9. Global Oral Vaccine for Human Revenue by Type (2018-2023) & ($ million)
Table 10. Global Oral Vaccine for Human Revenue Market Share by Type (2018-2023)
Table 11. Global Oral Vaccine for Human Sale Price by Type (2018-2023) & (US$/Unit)
Table 12. Global Oral Vaccine for Human Sales by Application (2018-2023) & (K Units)
Table 13. Global Oral Vaccine for Human Sales Market Share by Application (2018-2023)
Table 14. Global Oral Vaccine for Human Revenue by Application (2018-2023)
Table 15. Global Oral Vaccine for Human Revenue Market Share by Application (2018-2023)
Table 16. Global Oral Vaccine for Human Sale Price by Application (2018-2023) & (US$/Unit)
Table 17. Global Oral Vaccine for Human Sales by Company (2018-2023) & (K Units)
Table 18. Global Oral Vaccine for Human Sales Market Share by Company (2018-2023)
Table 19. Global Oral Vaccine for Human Revenue by Company (2018-2023) ($ Millions)
Table 20. Global Oral Vaccine for Human Revenue Market Share by Company (2018-2023)
Table 21. Global Oral Vaccine for Human Sale Price by Company (2018-2023) & (US$/Unit)
Table 22. Key Manufacturers Oral Vaccine for Human Producing Area Distribution and Sales Area
Table 23. Players Oral Vaccine for Human Products Offered
Table 24. Oral Vaccine for Human Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Oral Vaccine for Human Sales by Geographic Region (2018-2023) & (K Units)
Table 28. Global Oral Vaccine for Human Sales Market Share Geographic Region (2018-2023)
Table 29. Global Oral Vaccine for Human Revenue by Geographic Region (2018-2023) & ($ millions)
Table 30. Global Oral Vaccine for Human Revenue Market Share by Geographic Region (2018-2023)
Table 31. Global Oral Vaccine for Human Sales by Country/Region (2018-2023) & (K Units)
Table 32. Global Oral Vaccine for Human Sales Market Share by Country/Region (2018-2023)
Table 33. Global Oral Vaccine for Human Revenue by Country/Region (2018-2023) & ($ millions)
Table 34. Global Oral Vaccine for Human Revenue Market Share by Country/Region (2018-2023)
Table 35. Americas Oral Vaccine for Human Sales by Country (2018-2023) & (K Units)
Table 36. Americas Oral Vaccine for Human Sales Market Share by Country (2018-2023)
Table 37. Americas Oral Vaccine for Human Revenue by Country (2018-2023) & ($ Millions)
Table 38. Americas Oral Vaccine for Human Revenue Market Share by Country (2018-2023)
Table 39. Americas Oral Vaccine for Human Sales by Type (2018-2023) & (K Units)
Table 40. Americas Oral Vaccine for Human Sales by Application (2018-2023) & (K Units)
Table 41. APAC Oral Vaccine for Human Sales by Region (2018-2023) & (K Units)
Table 42. APAC Oral Vaccine for Human Sales Market Share by Region (2018-2023)
Table 43. APAC Oral Vaccine for Human Revenue by Region (2018-2023) & ($ Millions)
Table 44. APAC Oral Vaccine for Human Revenue Market Share by Region (2018-2023)
Table 45. APAC Oral Vaccine for Human Sales by Type (2018-2023) & (K Units)
Table 46. APAC Oral Vaccine for Human Sales by Application (2018-2023) & (K Units)
Table 47. Europe Oral Vaccine for Human Sales by Country (2018-2023) & (K Units)
Table 48. Europe Oral Vaccine for Human Sales Market Share by Country (2018-2023)
Table 49. Europe Oral Vaccine for Human Revenue by Country (2018-2023) & ($ Millions)
Table 50. Europe Oral Vaccine for Human Revenue Market Share by Country (2018-2023)
Table 51. Europe Oral Vaccine for Human Sales by Type (2018-2023) & (K Units)
Table 52. Europe Oral Vaccine for Human Sales by Application (2018-2023) & (K Units)
Table 53. Middle East & Africa Oral Vaccine for Human Sales by Country (2018-2023) & (K Units)
Table 54. Middle East & Africa Oral Vaccine for Human Sales Market Share by Country (2018-2023)
Table 55. Middle East & Africa Oral Vaccine for Human Revenue by Country (2018-2023) & ($ Millions)
Table 56. Middle East & Africa Oral Vaccine for Human Revenue Market Share by Country (2018-2023)
Table 57. Middle East & Africa Oral Vaccine for Human Sales by Type (2018-2023) & (K Units)
Table 58. Middle East & Africa Oral Vaccine for Human Sales by Application (2018-2023) & (K Units)
Table 59. Key Market Drivers & Growth Opportunities of Oral Vaccine for Human
Table 60. Key Market Challenges & Risks of Oral Vaccine for Human
Table 61. Key Industry Trends of Oral Vaccine for Human
Table 62. Oral Vaccine for Human Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Oral Vaccine for Human Distributors List
Table 65. Oral Vaccine for Human Customer List
Table 66. Global Oral Vaccine for Human Sales Forecast by Region (2024-2029) & (K Units)
Table 67. Global Oral Vaccine for Human Revenue Forecast by Region (2024-2029) & ($ millions)
Table 68. Americas Oral Vaccine for Human Sales Forecast by Country (2024-2029) & (K Units)
Table 69. Americas Oral Vaccine for Human Revenue Forecast by Country (2024-2029) & ($ millions)
Table 70. APAC Oral Vaccine for Human Sales Forecast by Region (2024-2029) & (K Units)
Table 71. APAC Oral Vaccine for Human Revenue Forecast by Region (2024-2029) & ($ millions)
Table 72. Europe Oral Vaccine for Human Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Europe Oral Vaccine for Human Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Middle East & Africa Oral Vaccine for Human Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Middle East & Africa Oral Vaccine for Human Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Global Oral Vaccine for Human Sales Forecast by Type (2024-2029) & (K Units)
Table 77. Global Oral Vaccine for Human Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 78. Global Oral Vaccine for Human Sales Forecast by Application (2024-2029) & (K Units)
Table 79. Global Oral Vaccine for Human Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 80. Merck Basic Information, Oral Vaccine for Human Manufacturing Base, Sales Area and Its Competitors
Table 81. Merck Oral Vaccine for Human Product Portfolios and Specifications
Table 82. Merck Oral Vaccine for Human Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Merck Main Business
Table 84. Merck Latest Developments
Table 85. GSK Basic Information, Oral Vaccine for Human Manufacturing Base, Sales Area and Its Competitors
Table 86. GSK Oral Vaccine for Human Product Portfolios and Specifications
Table 87. GSK Oral Vaccine for Human Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. GSK Main Business
Table 89. GSK Latest Developments
Table 90. Sanofi Basic Information, Oral Vaccine for Human Manufacturing Base, Sales Area and Its Competitors
Table 91. Sanofi Oral Vaccine for Human Product Portfolios and Specifications
Table 92. Sanofi Oral Vaccine for Human Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Sanofi Main Business
Table 94. Sanofi Latest Developments
Table 95. Lanzhou Institute Basic Information, Oral Vaccine for Human Manufacturing Base, Sales Area and Its Competitors
Table 96. Lanzhou Institute Oral Vaccine for Human Product Portfolios and Specifications
Table 97. Lanzhou Institute Oral Vaccine for Human Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Lanzhou Institute Main Business
Table 99. Lanzhou Institute Latest Developments
Table 100. Serum Institute Basic Information, Oral Vaccine for Human Manufacturing Base, Sales Area and Its Competitors
Table 101. Serum Institute Oral Vaccine for Human Product Portfolios and Specifications
Table 102. Serum Institute Oral Vaccine for Human Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Serum Institute Main Business
Table 104. Serum Institute Latest Developments
Table 105. Valneva Basic Information, Oral Vaccine for Human Manufacturing Base, Sales Area and Its Competitors
Table 106. Valneva Oral Vaccine for Human Product Portfolios and Specifications
Table 107. Valneva Oral Vaccine for Human Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Valneva Main Business
Table 109. Valneva Latest Developments
Table 110. Shanghai United Cell Basic Information, Oral Vaccine for Human Manufacturing Base, Sales Area and Its Competitors
Table 111. Shanghai United Cell Oral Vaccine for Human Product Portfolios and Specifications
Table 112. Shanghai United Cell Oral Vaccine for Human Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Shanghai United Cell Main Business
Table 114. Shanghai United Cell Latest Developments
Table 115. Bibcol Basic Information, Oral Vaccine for Human Manufacturing Base, Sales Area and Its Competitors
Table 116. Bibcol Oral Vaccine for Human Product Portfolios and Specifications
Table 117. Bibcol Oral Vaccine for Human Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. Bibcol Main Business
Table 119. Bibcol Latest Developments
Table 120. PaxVax Basic Information, Oral Vaccine for Human Manufacturing Base, Sales Area and Its Competitors
Table 121. PaxVax Oral Vaccine for Human Product Portfolios and Specifications
Table 122. PaxVax Oral Vaccine for Human Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. PaxVax Main Business
Table 124. PaxVax Latest Developments
Table 125. Vabiotech Basic Information, Oral Vaccine for Human Manufacturing Base, Sales Area and Its Competitors
Table 126. Vabiotech Oral Vaccine for Human Product Portfolios and Specifications
Table 127. Vabiotech Oral Vaccine for Human Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 128. Vabiotech Main Business
Table 129. Vabiotech Latest Developments
Table 130. Tiantan Biological Basic Information, Oral Vaccine for Human Manufacturing Base, Sales Area and Its Competitors
Table 131. Tiantan Biological Oral Vaccine for Human Product Portfolios and Specifications
Table 132. Tiantan Biological Oral Vaccine for Human Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 133. Tiantan Biological Main Business
Table 134. Tiantan Biological Latest Developments
Table 135. EuBiologics Basic Information, Oral Vaccine for Human Manufacturing Base, Sales Area and Its Competitors
Table 136. EuBiologics Oral Vaccine for Human Product Portfolios and Specifications
Table 137. EuBiologics Oral Vaccine for Human Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 138. EuBiologics Main Business
Table 139. EuBiologics Latest Developments
Table 140. Panacea Biotec Ltd Basic Information, Oral Vaccine for Human Manufacturing Base, Sales Area and Its Competitors
Table 141. Panacea Biotec Ltd Oral Vaccine for Human Product Portfolios and Specifications
Table 142. Panacea Biotec Ltd Oral Vaccine for Human Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 143. Panacea Biotec Ltd Main Business
Table 144. Panacea Biotec Ltd Latest Developments
Table 145. Bio-Med Basic Information, Oral Vaccine for Human Manufacturing Base, Sales Area and Its Competitors
Table 146. Bio-Med Oral Vaccine for Human Product Portfolios and Specifications
Table 147. Bio-Med Oral Vaccine for Human Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 148. Bio-Med Main Business
Table 149. Bio-Med Latest Developments
Table 150. Halfkin Bio-Pharmaceuticals Basic Information, Oral Vaccine for Human Manufacturing Base, Sales Area and Its Competitors
Table 151. Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Product Portfolios and Specifications
Table 152. Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 153. Halfkin Bio-Pharmaceuticals Main Business
Table 154. Halfkin Bio-Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Picture of Oral Vaccine for Human
Figure 2. Oral Vaccine for Human Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Oral Vaccine for Human Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Oral Vaccine for Human Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Oral Vaccine for Human Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Rotavirus Vaccine
Figure 10. Product Picture of Cholera Vaccine
Figure 11. Product Picture of Oral Polio Vaccine
Figure 12. Product Picture of Other
Figure 13. Global Oral Vaccine for Human Sales Market Share by Type in 2022
Figure 14. Global Oral Vaccine for Human Revenue Market Share by Type (2018-2023)
Figure 15. Oral Vaccine for Human Consumed in Public
Figure 16. Global Oral Vaccine for Human Market: Public (2018-2023) & (K Units)
Figure 17. Oral Vaccine for Human Consumed in Private
Figure 18. Global Oral Vaccine for Human Market: Private (2018-2023) & (K Units)
Figure 19. Global Oral Vaccine for Human Sales Market Share by Application (2022)
Figure 20. Global Oral Vaccine for Human Revenue Market Share by Application in 2022
Figure 21. Oral Vaccine for Human Sales Market by Company in 2022 (K Units)
Figure 22. Global Oral Vaccine for Human Sales Market Share by Company in 2022
Figure 23. Oral Vaccine for Human Revenue Market by Company in 2022 ($ Million)
Figure 24. Global Oral Vaccine for Human Revenue Market Share by Company in 2022
Figure 25. Global Oral Vaccine for Human Sales Market Share by Geographic Region (2018-2023)
Figure 26. Global Oral Vaccine for Human Revenue Market Share by Geographic Region in 2022
Figure 27. Americas Oral Vaccine for Human Sales 2018-2023 (K Units)
Figure 28. Americas Oral Vaccine for Human Revenue 2018-2023 ($ Millions)
Figure 29. APAC Oral Vaccine for Human Sales 2018-2023 (K Units)
Figure 30. APAC Oral Vaccine for Human Revenue 2018-2023 ($ Millions)
Figure 31. Europe Oral Vaccine for Human Sales 2018-2023 (K Units)
Figure 32. Europe Oral Vaccine for Human Revenue 2018-2023 ($ Millions)
Figure 33. Middle East & Africa Oral Vaccine for Human Sales 2018-2023 (K Units)
Figure 34. Middle East & Africa Oral Vaccine for Human Revenue 2018-2023 ($ Millions)
Figure 35. Americas Oral Vaccine for Human Sales Market Share by Country in 2022
Figure 36. Americas Oral Vaccine for Human Revenue Market Share by Country in 2022
Figure 37. Americas Oral Vaccine for Human Sales Market Share by Type (2018-2023)
Figure 38. Americas Oral Vaccine for Human Sales Market Share by Application (2018-2023)
Figure 39. United States Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 40. Canada Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 41. Mexico Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 42. Brazil Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 43. APAC Oral Vaccine for Human Sales Market Share by Region in 2022
Figure 44. APAC Oral Vaccine for Human Revenue Market Share by Regions in 2022
Figure 45. APAC Oral Vaccine for Human Sales Market Share by Type (2018-2023)
Figure 46. APAC Oral Vaccine for Human Sales Market Share by Application (2018-2023)
Figure 47. China Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 48. Japan Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 49. South Korea Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 50. Southeast Asia Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 51. India Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 52. Australia Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 53. China Taiwan Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 54. Europe Oral Vaccine for Human Sales Market Share by Country in 2022
Figure 55. Europe Oral Vaccine for Human Revenue Market Share by Country in 2022
Figure 56. Europe Oral Vaccine for Human Sales Market Share by Type (2018-2023)
Figure 57. Europe Oral Vaccine for Human Sales Market Share by Application (2018-2023)
Figure 58. Germany Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 59. France Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 60. UK Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 61. Italy Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 62. Russia Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 63. Middle East & Africa Oral Vaccine for Human Sales Market Share by Country in 2022
Figure 64. Middle East & Africa Oral Vaccine for Human Revenue Market Share by Country in 2022
Figure 65. Middle East & Africa Oral Vaccine for Human Sales Market Share by Type (2018-2023)
Figure 66. Middle East & Africa Oral Vaccine for Human Sales Market Share by Application (2018-2023)
Figure 67. Egypt Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 68. South Africa Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 69. Israel Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 70. Turkey Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 71. GCC Country Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of Oral Vaccine for Human in 2022
Figure 73. Manufacturing Process Analysis of Oral Vaccine for Human
Figure 74. Industry Chain Structure of Oral Vaccine for Human
Figure 75. Channels of Distribution
Figure 76. Global Oral Vaccine for Human Sales Market Forecast by Region (2024-2029)
Figure 77. Global Oral Vaccine for Human Revenue Market Share Forecast by Region (2024-2029)
Figure 78. Global Oral Vaccine for Human Sales Market Share Forecast by Type (2024-2029)
Figure 79. Global Oral Vaccine for Human Revenue Market Share Forecast by Type (2024-2029)
Figure 80. Global Oral Vaccine for Human Sales Market Share Forecast by Application (2024-2029)
Figure 81. Global Oral Vaccine for Human Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Oral Vaccine for Human
Figure 2. Oral Vaccine for Human Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Oral Vaccine for Human Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Oral Vaccine for Human Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Oral Vaccine for Human Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Rotavirus Vaccine
Figure 10. Product Picture of Cholera Vaccine
Figure 11. Product Picture of Oral Polio Vaccine
Figure 12. Product Picture of Other
Figure 13. Global Oral Vaccine for Human Sales Market Share by Type in 2022
Figure 14. Global Oral Vaccine for Human Revenue Market Share by Type (2018-2023)
Figure 15. Oral Vaccine for Human Consumed in Public
Figure 16. Global Oral Vaccine for Human Market: Public (2018-2023) & (K Units)
Figure 17. Oral Vaccine for Human Consumed in Private
Figure 18. Global Oral Vaccine for Human Market: Private (2018-2023) & (K Units)
Figure 19. Global Oral Vaccine for Human Sales Market Share by Application (2022)
Figure 20. Global Oral Vaccine for Human Revenue Market Share by Application in 2022
Figure 21. Oral Vaccine for Human Sales Market by Company in 2022 (K Units)
Figure 22. Global Oral Vaccine for Human Sales Market Share by Company in 2022
Figure 23. Oral Vaccine for Human Revenue Market by Company in 2022 ($ Million)
Figure 24. Global Oral Vaccine for Human Revenue Market Share by Company in 2022
Figure 25. Global Oral Vaccine for Human Sales Market Share by Geographic Region (2018-2023)
Figure 26. Global Oral Vaccine for Human Revenue Market Share by Geographic Region in 2022
Figure 27. Americas Oral Vaccine for Human Sales 2018-2023 (K Units)
Figure 28. Americas Oral Vaccine for Human Revenue 2018-2023 ($ Millions)
Figure 29. APAC Oral Vaccine for Human Sales 2018-2023 (K Units)
Figure 30. APAC Oral Vaccine for Human Revenue 2018-2023 ($ Millions)
Figure 31. Europe Oral Vaccine for Human Sales 2018-2023 (K Units)
Figure 32. Europe Oral Vaccine for Human Revenue 2018-2023 ($ Millions)
Figure 33. Middle East & Africa Oral Vaccine for Human Sales 2018-2023 (K Units)
Figure 34. Middle East & Africa Oral Vaccine for Human Revenue 2018-2023 ($ Millions)
Figure 35. Americas Oral Vaccine for Human Sales Market Share by Country in 2022
Figure 36. Americas Oral Vaccine for Human Revenue Market Share by Country in 2022
Figure 37. Americas Oral Vaccine for Human Sales Market Share by Type (2018-2023)
Figure 38. Americas Oral Vaccine for Human Sales Market Share by Application (2018-2023)
Figure 39. United States Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 40. Canada Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 41. Mexico Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 42. Brazil Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 43. APAC Oral Vaccine for Human Sales Market Share by Region in 2022
Figure 44. APAC Oral Vaccine for Human Revenue Market Share by Regions in 2022
Figure 45. APAC Oral Vaccine for Human Sales Market Share by Type (2018-2023)
Figure 46. APAC Oral Vaccine for Human Sales Market Share by Application (2018-2023)
Figure 47. China Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 48. Japan Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 49. South Korea Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 50. Southeast Asia Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 51. India Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 52. Australia Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 53. China Taiwan Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 54. Europe Oral Vaccine for Human Sales Market Share by Country in 2022
Figure 55. Europe Oral Vaccine for Human Revenue Market Share by Country in 2022
Figure 56. Europe Oral Vaccine for Human Sales Market Share by Type (2018-2023)
Figure 57. Europe Oral Vaccine for Human Sales Market Share by Application (2018-2023)
Figure 58. Germany Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 59. France Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 60. UK Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 61. Italy Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 62. Russia Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 63. Middle East & Africa Oral Vaccine for Human Sales Market Share by Country in 2022
Figure 64. Middle East & Africa Oral Vaccine for Human Revenue Market Share by Country in 2022
Figure 65. Middle East & Africa Oral Vaccine for Human Sales Market Share by Type (2018-2023)
Figure 66. Middle East & Africa Oral Vaccine for Human Sales Market Share by Application (2018-2023)
Figure 67. Egypt Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 68. South Africa Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 69. Israel Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 70. Turkey Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 71. GCC Country Oral Vaccine for Human Revenue Growth 2018-2023 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of Oral Vaccine for Human in 2022
Figure 73. Manufacturing Process Analysis of Oral Vaccine for Human
Figure 74. Industry Chain Structure of Oral Vaccine for Human
Figure 75. Channels of Distribution
Figure 76. Global Oral Vaccine for Human Sales Market Forecast by Region (2024-2029)
Figure 77. Global Oral Vaccine for Human Revenue Market Share Forecast by Region (2024-2029)
Figure 78. Global Oral Vaccine for Human Sales Market Share Forecast by Type (2024-2029)
Figure 79. Global Oral Vaccine for Human Revenue Market Share Forecast by Type (2024-2029)
Figure 80. Global Oral Vaccine for Human Sales Market Share Forecast by Application (2024-2029)
Figure 81. Global Oral Vaccine for Human Revenue Market Share Forecast by Application (2024-2029)
